BUDESONIDE [USP-RS]

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

92 API Suppliers, 26 USDMF, 28 CEP/COS, 7 JDMF, 8 EU WC, 16 KDMF, 37 NDC API, 47 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

150 Drugs in Development

150 Drugs in Development

INTERMEDIATES

7 Intermediate Suppliers

7 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

1155 FDF Dossiers, 54 FDA Orange Book, 966 Europe, 23 Canada, 18 Australia, 39 South Africa, 55 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 9MG, AEROSOL, FOAM;RECTAL - 2MG/ACTUATION, SPRAY, METERED;NASAL - 0.032MG/SPRAY, SUSPENSION;INHALATION - 0.25MG/2ML, SUSPENSION;INHALATION - 0.5MG/2ML, SUSPENSION;INHALATION - 1MG/2ML, CAPSULE, DELAYED RELEASE;ORAL - 6MG, CAPSULE, DELAYED RELEASE;ORAL - 9MG, CAPSULE, DELAYED RELEASE;ORAL - 3MG, AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH, AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH

RELATED EXCIPIENT COMPANIES

4 Evonik, 1 Rochem International Inc, 5 SPI Pharma, 13 DKSH, 3 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 9 Kirsch Pharma, 4 ACG Worldwide, 11 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 23 BASF, 1 CD Formulation, 1 Clariant, 14 Corel Pharma Chem, 4 DFE Pharma, 3 Doshion Polyscience, 1 Esteem Industries, 2 Finar, 10 Gangwal Chemicals, 8 Ideal Cures, 2 Ingredion Pharma Solutions, 20 Kerry, 2 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 16 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 18 Roquette, 14 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 Silverline Chemicals, 4 The Dow Chemical Company, 2 Valens Pharmachem, 2 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

64 Coating Systems & Additives, 53 Fillers, Diluents & Binders, 42 Thickeners and Stabilizers, 35 Controlled & Modified Release, 25 Solubilizers, 23 Granulation, 23 Direct Compression, 20 Taste Masking, 20 Parenteral, 20 Film Formers & Plasticizers, 19 Topical, 18 Lubricants & Glidants, 11 Co-Processed Excipients, 10 Emulsifying Agents, 10 Rheology Modifiers, 9 Empty Capsules, 9 Disintegrants & Superdisintegrants, 8 Chewable & Orodispersible Aids, 5 Surfactant & Foaming Agents, 5 API Stability Enhancers, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 2 Stock Recap #PipelineProspector, 140 News #PharmaBuzz

GLOBAL SALES INFORMATION

34 US Medicaid Prescriptions, 186 Regulatory FDF Prices, 51 Annual Reports

MARKET PLACE

20 APIs, 17 FDF Dossiers, 1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

39 US Patents, 4 US Exclusivities, 16 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 21 USP, 15 Others

ANALYTICAL

3 BioAnalytical Methods

3 BioAnalytical Methods

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 20929 / DOSAGE - SUSPENSION;INHALATION - 0.5MG/2ML

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
BUDESONIDE(UNII: Q3OKS62Q6X) (BUDESONIDE - UNII:Q3OKS62Q6X)	BUDESONIDE	0.5mg in 2

Inactive Ingredients

Ingredient Name	Cardinal Health	The Ritedose Corporation	A-S Medication Solutions	Actavis Pharma, Inc.	American Health Packaging	Amneal Pharmaceuticals of New York LLC	Catalent Pharma Solutions, LLC	Cipla USA Inc.	Exelan Pharmaceuticals, Inc.	NorthStar RxLLC	Preferred Pharmaceuticals Inc.	Preferred Pharmaceuticals, Inc.	Apotex Corp.
ANHYDROUS CITRIC ACID(XF417D3PSL)
CITRIC ACID MONOHYDRATE(2968PHW8QP)
EDETATE DISODIUM(7FLD91C86K)
POLYSORBATE 80(6OZP39ZG8H)
SODIUM CHLORIDE (451W47IQ8X)
SODIUM CHLORIDE(451W47IQ8X)
SODIUM CITRATE(1Q73Q2JULR)
SODIUM CITRATE, UNSPECIFIED FORM(1Q73Q2JULR)
trisodium citrate dihydrate(B22547B95K)
WATER(059QF0KO0R)

Setid 9e6641a9 32c8 422a A1d6 3aba08fd1400 Applno 20929 Form Suspension Inhalation Dosage 0 5mg 2ml - Drug Product Composition: BUDESONIDE [USP-RS]